1. Home
  2. FN vs INSM Comparison

FN vs INSM Comparison

Compare FN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabrinet

FN

Fabrinet

HOLD

Current Price

$481.17

Market Cap

20.3B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$109.72

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FN
INSM
Founded
1999
1988
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.3B
23.0B
IPO Year
2007
2000

Fundamental Metrics

Financial Performance
Metric
FN
INSM
Price
$481.17
$109.72
Analyst Decision
Buy
Strong Buy
Analyst Count
8
24
Target Price
$513.43
$201.17
AVG Volume (30 Days)
826.3K
3.7M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
13.21
N/A
EPS
9.22
N/A
Revenue
$3,419,327,000.00
N/A
Revenue This Year
$36.87
$182.31
Revenue Next Year
$17.91
$65.19
P/E Ratio
$51.38
N/A
Revenue Growth
18.60
N/A
52 Week Low
$272.49
$90.39
52 Week High
$748.89
$212.75

Technical Indicators

Market Signals
Indicator
FN
INSM
Relative Strength Index (RSI) 37.13 51.94
Support Level $429.50 $98.90
Resistance Level $508.51 $166.81
Average True Range (ATR) 33.08 4.67
MACD -3.31 1.13
Stochastic Oscillator 18.70 46.19

Price Performance

Historical Comparison
FN
INSM

About FN Fabrinet

Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: